Aerie's Rhopressa Approved Early For Glaucoma, 2018 Launch Planned

The first of Aerie's two glaucoma candidates, Rhopressa, was approved in the US and a submission for combination product Roclatan is expected next year. Rhopressa may have muted uptake in 2018, however, since it won't launch until the second quarter and half of its market is covered by Medicare Part D.

Close-up of blue eye. High Technologies in the futuristic. : cataract

Aerie Pharmaceuticals Inc. will launch its first of two glaucoma drugs in the middle of the second quarter of 2018 as planned even though the US FDA approved Rhopressa two months earlier than expected. Even then it will take another seven or eight months for half of the drug's patients to gain access.

Irvine, Calif.-based Aerie said on Dec. 18 that Rhopressa (netarsudil ophthalmic solution 0.02%) was approved for the lowering of elevated...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip